Development of sulfanegen for mass cyanide casualties

Steven Patterson, Bryant Moeller, Herbert T. Nagasawa, Robert Vince, Daune L. Crankshaw, Jacquie Briggs, Michael W. Stutelberg, Chakravarthy V. Vinnakota, Brian A. Logue

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.

Original languageEnglish (US)
Pages (from-to)202-209
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume1374
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Mass Casualty Incidents
Cyanides
Antidotes
Occupational Accidents
Detoxification
Unconsciousness
Poisons
Intramuscular Injections
Respiratory Insufficiency
Intravenous Administration
Poisoning
Brain Injuries
Brain
Accidents
Animals
Animal Models
Heart Failure
Adenosine Triphosphate
Personnel
Oxygen

Keywords

  • 3-MST
  • 3-mercaptopyruvate sulfurtransferase
  • cyanide antidote
  • cyanide poisoning
  • sulfanegen

Cite this

Patterson, S., Moeller, B., Nagasawa, H. T., Vince, R., Crankshaw, D. L., Briggs, J., ... Logue, B. A. (2016). Development of sulfanegen for mass cyanide casualties. Annals of the New York Academy of Sciences, 1374(1), 202-209. https://doi.org/10.1111/nyas.13114

Development of sulfanegen for mass cyanide casualties. / Patterson, Steven; Moeller, Bryant; Nagasawa, Herbert T.; Vince, Robert; Crankshaw, Daune L.; Briggs, Jacquie; Stutelberg, Michael W.; Vinnakota, Chakravarthy V.; Logue, Brian A.

In: Annals of the New York Academy of Sciences, Vol. 1374, No. 1, 01.01.2016, p. 202-209.

Research output: Contribution to journalArticle

Patterson, S, Moeller, B, Nagasawa, HT, Vince, R, Crankshaw, DL, Briggs, J, Stutelberg, MW, Vinnakota, CV & Logue, BA 2016, 'Development of sulfanegen for mass cyanide casualties', Annals of the New York Academy of Sciences, vol. 1374, no. 1, pp. 202-209. https://doi.org/10.1111/nyas.13114
Patterson, Steven ; Moeller, Bryant ; Nagasawa, Herbert T. ; Vince, Robert ; Crankshaw, Daune L. ; Briggs, Jacquie ; Stutelberg, Michael W. ; Vinnakota, Chakravarthy V. ; Logue, Brian A. / Development of sulfanegen for mass cyanide casualties. In: Annals of the New York Academy of Sciences. 2016 ; Vol. 1374, No. 1. pp. 202-209.
@article{660927e745f34c75a0e0c74a01a6bcb2,
title = "Development of sulfanegen for mass cyanide casualties",
abstract = "Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.",
keywords = "3-MST, 3-mercaptopyruvate sulfurtransferase, cyanide antidote, cyanide poisoning, sulfanegen",
author = "Steven Patterson and Bryant Moeller and Nagasawa, {Herbert T.} and Robert Vince and Crankshaw, {Daune L.} and Jacquie Briggs and Stutelberg, {Michael W.} and Vinnakota, {Chakravarthy V.} and Logue, {Brian A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/nyas.13114",
language = "English (US)",
volume = "1374",
pages = "202--209",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Development of sulfanegen for mass cyanide casualties

AU - Patterson, Steven

AU - Moeller, Bryant

AU - Nagasawa, Herbert T.

AU - Vince, Robert

AU - Crankshaw, Daune L.

AU - Briggs, Jacquie

AU - Stutelberg, Michael W.

AU - Vinnakota, Chakravarthy V.

AU - Logue, Brian A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.

AB - Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.

KW - 3-MST

KW - 3-mercaptopyruvate sulfurtransferase

KW - cyanide antidote

KW - cyanide poisoning

KW - sulfanegen

UR - http://www.scopus.com/inward/record.url?scp=84983541292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983541292&partnerID=8YFLogxK

U2 - 10.1111/nyas.13114

DO - 10.1111/nyas.13114

M3 - Article

VL - 1374

SP - 202

EP - 209

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -